Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma |
| Type de publication | Journal Article |
| Year of Publication | 2016 |
| Auteurs | Bertaut A, Truntzer C, Madkouri R, Kaderbhai CGuillaume, Derangere V, Vincent J, Chauffert B, Aubriot-Lorton MHelene, Farah W, Mourier KLuc, Boidot R, Ghiringhelli F |
| Journal | ONCOTARGET |
| Volume | 7 |
| Pagination | 70948-70958 |
| Date Published | OCT 25 |
| Type of Article | Article |
| Mots-clés | Bevacizumab, Glioblastoma, prognosistic factor |
| Résumé | {Bevacizumab is used to treat glioblastoma; however, no current biomarker predicts its efficacy. We used an exploratory cohort of patients treated with the radiochemotherapy then bevacizumab or chemotherapy at recurrence (N = 265). Bevacizumab use increased median overall survival (OS) 18.7 vs 11.3 months |
| DOI | 10.18632/oncotarget.10898 |